Theriva Biologics receives conversion notice for 135,431 Series C Preferred shares into ~888K common shares

Theriva Biologics, Inc.

Holder converted 135,431 Series C Preferred shares into 888,072 common shares at $1.22 per share.
Conversion increases outstanding common shares by approximately 888,000, diluting existing shareholders.
Notice received May 13, 2024; conversion effective upon notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.